LONDON, Oct 8 (Reuters) - Pfizer ( PFE ) and its German

partner BioNTech on Tuesday won their attempt to

invalidate two of rival CureVac's ( CVAC ) patents at London's

High Court.

Pfizer ( PFE ) and BioNTech had filed their lawsuit in September

2022 over patents relating to messenger RNA (mRNA) technology,

which underpins Pfizer ( PFE ) and BioNTech's COVID-19 vaccine.